Literature DB >> 15857974

High-level expression of Marek's disease virus glycoprotein C is detrimental to virus growth in vitro.

B Karsten Tischer1, Daniel Schumacher, Danièlle Chabanne-Vautherot, Vladimir Zelnik, Jean-François Vautherot, Nikolaus Osterrieder.   

Abstract

Expression levels of Marek's disease virus (MDV) glycoprotein C (gC) are significantly reduced after serial virus passage in cell culture. Reduced gC expression coincides with enhanced MDV growth in vitro and attenuation. To analyze this phenomenon in detail, a full-length infectious MDV clone was modified by Red-based and shuttle mutagenesis in Escherichia coli. Besides a gC-negative deletion mutant harboring a kanamycin resistance gene, a markerless mutant with the U(L)44 gene deleted was constructed. On the basis of this deletion mutant, the original or a modified U(L)44 gene with a mutated start codon (AUG-->ACG) was reinserted into the authentic locus. Similarly, mutants expressing authentic gC or the start codon mutation under the control of a strong constitutive promoter were generated. In vitro studies demonstrated that gC deletion mutants induced twofold-larger plaques than the parental virus did, whereas constitutive overexpression of the glycoprotein resulted in a more than twofold reduction in plaque size. In addition, plaque sizes of the gC deletion mutant were reduced when virus was grown using supernatants from cells infected with parental virus, but supernatants obtained from cells infected with the gC deletion mutant had no measurable effect on plaque size. The results indicated that (i) expression of MDV gC, albeit at low levels in a highly passaged virus, had a significant negative impact on the cell-to-cell spread capabilities of the virus, which was alleviated in its absence and exacerbated by its overexpression, and that (ii) this activity was mediated by the secreted form of MDV gC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857974      PMCID: PMC1091721          DOI: 10.1128/JVI.79.10.5889-5899.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus.

Authors:  L F Lee; P Wu; D Sui; D Ren; J Kamil; H J Kung; R L Witter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Rapid modification of bacterial artificial chromosomes by ET-recombination.

Authors:  J P Muyrers; Y Zhang; G Testa; A F Stewart
Journal:  Nucleic Acids Res       Date:  1999-03-15       Impact factor: 16.971

3.  Identification and characterization of bovine herpesvirus-1 glycoproteins E and I.

Authors:  N Yoshitake; X Xuan; H Otsuka
Journal:  J Gen Virol       Date:  1997-06       Impact factor: 3.891

4.  VP16 interacts via its activation domain with VP22, a tegument protein of herpes simplex virus, and is relocated to a novel macromolecular assembly in coexpressing cells.

Authors:  G Elliott; G Mouzakitis; P O'Hare
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

5.  Identification and characterization of pseudorabies virus glycoprotein gM as a nonessential virion component.

Authors:  J M Dijkstra; N Visser; T C Mettenleiter; B G Klupp
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Increased virulence of Marek's disease virus field isolates.

Authors:  R L Witter
Journal:  Avian Dis       Date:  1997 Jan-Mar       Impact factor: 1.577

7.  Relationship between the immunosuppressive potential and the pathotype of Marek's disease virus isolates.

Authors:  B W Calnek; R W Harris; C Buscaglia; K A Schat; B Lucio
Journal:  Avian Dis       Date:  1998 Jan-Mar       Impact factor: 1.577

8.  The equine herpesvirus 1 glycoprotein gp21/22a, the herpes simplex virus type 1 gM homolog, is involved in virus penetration and cell-to-cell spread of virions.

Authors:  N Osterrieder; A Neubauer; C Brandmuller; B Braun; O R Kaaden; J D Baines
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

10.  Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

Authors:  J F Moffat; L Zerboni; P R Kinchington; C Grose; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more
  18 in total

1.  The Herpesviridae Conserved Multifunctional Infected-Cell Protein 27 (ICP27) Is Important but Not Required for Replication and Oncogenicity of Marek's Disease Alphaherpesvirus.

Authors:  Nagendraprabhu Ponnuraj; Yung-Tien Tien; Widaliz Vega-Rodriguez; Andrea Krieter; Keith W Jarosinski
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Marek's disease virus expresses multiple UL44 (gC) variants through mRNA splicing that are all required for efficient horizontal transmission.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus.

Authors:  Stephen J Spatz; Yuguang Zhao; Lawrence Petherbridge; Lorraine P Smith; Susan J Baigent; Venugopal Nair
Journal:  Virus Genes       Date:  2007-08-25       Impact factor: 2.332

4.  Further analysis of Marek's disease virus horizontal transmission confirms that U(L)44 (gC) and U(L)13 protein kinase activity are essential, while U(S)2 is nonessential.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

5.  Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder; Venugopal K Nair; Karel A Schat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Genomic deletions and mutations resulting in the loss of eight genes reduce the in vivo replication capacity of Meleagrid herpesvirus 1.

Authors:  Timothy J Mahony; Robyn N Hall; Stephen Walkden-Brown; Joanne Meers; Jennifer L Gravel; Lani West; Vanessa Hardy; A F M Fakhrul Islam; Elizabeth V Fowler; Neena Mitter
Journal:  Virus Genes       Date:  2015-07-07       Impact factor: 2.332

7.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

8.  Horizontal transmission of Marek's disease virus requires US2, the UL13 protein kinase, and gC.

Authors:  Keith W Jarosinski; Neil G Margulis; Jeremy P Kamil; Stephen J Spatz; Venugopal K Nair; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

9.  The Tegument Protein pUL47 of Marek's Disease Virus Is Necessary for Horizontal Transmission and Is Important for Expression of Glycoprotein gC.

Authors:  Aurélien Chuard; Katia Courvoisier-Guyader; Sylvie Rémy; Stephen Spatz; Caroline Denesvre; David Pasdeloup
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

10.  The Marek's disease virus (MDV) protein encoded by the UL17 ortholog is essential for virus growth.

Authors:  Najat Chbab; Danièle Chabanne-Vautherot; Annick Francineau; Nikolaus Osterrieder; Caroline Denesvre; Jean-François Vautherot
Journal:  Vet Res       Date:  2009-03-14       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.